Harbin Medisan Pharmaceutical Co Ltd (002900) — Net Asset Quality Index
Harbin Medisan Pharmaceutical Co Ltd (002900) has a Net Asset Quality Index of 52.8% as of September 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥3.61 Billion minus total liabilities of CN¥1.70 Billion yields net assets of CN¥1.90 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Check 002900 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
Harbin Medisan Pharmaceutical Co Ltd Net Asset Quality Index Over Time (2012–2024)
This chart shows how Harbin Medisan Pharmaceutical Co Ltd's Net Asset Quality Index has evolved across 13 annual periods from 2012 to 2024. As of September 2025, the index stands at 52.8%, representing net assets of CN¥1.90 Billion against total assets of CN¥3.61 Billion CNY. See working capital position of Harbin Medisan Pharmaceutical Co Ltd to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Harbin Medisan Pharmaceutical Co Ltd (2012–2024)
The table below presents the year-by-year Net Asset Quality Index for Harbin Medisan Pharmaceutical Co Ltd from 2012 to 2024, covering 13 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see Harbin Medisan Pharmaceutical Co Ltd stock valuation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 56.9% | CN¥2.16 Billion | CN¥3.80 Billion | CN¥1.64 Billion | ▼ -5.4 pp |
| 2023 | 62.4% | CN¥2.15 Billion | CN¥3.44 Billion | CN¥1.29 Billion | ▼ -0.2 pp |
| 2022 | 62.6% | CN¥2.05 Billion | CN¥3.28 Billion | CN¥1.22 Billion | ▼ -6.4 pp |
| 2021 | 69.0% | CN¥2.12 Billion | CN¥3.07 Billion | CN¥949.04 Million | ▼ -3.1 pp |
| 2020 | 72.2% | CN¥1.79 Billion | CN¥2.48 Billion | CN¥691.18 Million | ▲ +2.9 pp |
| 2019 | 69.3% | CN¥1.85 Billion | CN¥2.67 Billion | CN¥820.44 Million | ▼ -9.1 pp |
| 2018 | 78.4% | CN¥1.97 Billion | CN¥2.51 Billion | CN¥543.78 Million | ▼ -5.7 pp |
| 2017 | 84.0% | CN¥1.83 Billion | CN¥2.18 Billion | CN¥348.80 Million | ▲ +14.7 pp |
| 2016 | 69.3% | CN¥808.17 Million | CN¥1.17 Billion | CN¥358.01 Million | ▲ +0.2 pp |
| 2015 | 69.1% | CN¥727.97 Million | CN¥1.05 Billion | CN¥324.95 Million | ▲ +6.4 pp |
| 2014 | 62.8% | CN¥609.16 Million | CN¥970.46 Million | CN¥361.30 Million | ▲ +20.2 pp |
| 2013 | 42.6% | CN¥365.13 Million | CN¥857.75 Million | CN¥492.63 Million | ▼ -5.1 pp |
| 2012 | 47.7% | CN¥342.72 Million | CN¥719.01 Million | CN¥376.29 Million | — |